The different experimental models of bystander activity substantiate the clinical observation that in lymphoma patients, brentuximab vedotin has shown clinical efficacy regardless of the level of CD30 expression including CD30‐negative tumour cells 21, 22. This evidence concerns the gene TNFRSF8 and lymphoma.